| Literature DB >> 33208459 |
Jaclyn C Law1, Wan Hon Koh1,2, Patrick Budylowski2,3, Jonah Lin1, FengYun Yue2, Kento T Abe4,5, Bhavisha Rathod4, Melanie Girard1, Zhijie Li5, James M Rini5,6, Samira Mubareka7,8, Allison McGeer4,8, Adrienne K Chan7,9, Anne-Claude Gingras4,5, Tania H Watts10, Mario A Ostrowski1,2,11.
Abstract
There is a pressing need for an in-depth understanding of immunity to SARS-CoV-2. In this study, we investigated human T cell recall responses to fully glycosylated spike trimer, recombinant N protein, as well as to S, N, M, and E peptide pools in the early convalescent phase and compared them with influenza-specific memory responses from the same donors. All subjects showed SARS-CoV-2-specific T cell responses to at least one Ag. Both SARS-CoV-2-specific and influenza-specific CD4+ T cell responses were predominantly of the central memory phenotype; however SARS-CoV-2-specific CD4+ T cells exhibited a lower IFN-γ to TNF ratio compared with influenza-specific memory responses from the same donors, independent of disease severity. SARS-CoV-2-specific T cells were less multifunctional than influenza-specific T cells, particularly in severe cases, potentially suggesting exhaustion. Most SARS-CoV-2-convalescent subjects also produced IFN-γ in response to seasonal OC43 S protein. We observed granzyme B+/IFN-γ+, CD4+, and CD8+ proliferative responses to peptide pools in most individuals, with CD4+ T cell responses predominating over CD8+ T cell responses. Peripheral T follicular helper (pTfh) responses to S or N strongly correlated with serum neutralization assays as well as receptor binding domain-specific IgA; however, the frequency of pTfh responses to SARS-CoV-2 was lower than the frequency of pTfh responses to influenza virus. Overall, T cell responses to SARS-CoV-2 are robust; however, CD4+ Th1 responses predominate over CD8+ T cell responses, have a more inflammatory profile, and have a weaker pTfh response than the response to influenza virus within the same donors, potentially contributing to COVID-19 disease.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33208459 PMCID: PMC7750861 DOI: 10.4049/jimmunol.2001067
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422